Search Results
Apr 22, 2026, 12:40 ET First Traveling Bedside PDA Closure Performed at Nicklaus Children's Hospital Fort Lauderdale NICU
of transporting a fragile babyEliminated risks associated with transporting fragile newbornsEarly intervention that allows improved lung recoveryA Minimally invasive technique that involves a small catheter to close the vessel without a chest incisionA small blood
More news about: Nicklaus Children's Health System
Apr 22, 2026, 11:40 ET Global Lung Cancer Therapeutics Market to Reach USD 142.3 Billion as Precision Medicine and Immunotherapy Redefine Oncology Care | Future Market Insights
https://www.futuremarketinsights.com/checkout/422Related ReportsLung Cancer Diagnostics Market: https://www.futuremarketinsights.com/reports/lung-cancer-diagnostics-marketLung Cancer Molecular Biomarker Market:
More news about: Future Market Insights
Apr 22, 2026, 11:01 ET Pulmonary Fibrosis Foundation Expands Leadership To Drive Scientific and Partnership Strategy
Network, which supports specialized interstitial lung disease centers across the country, and has overseen the PFF Registry, a key research resource for patients, families, caregivers and lung transplant recipients affected by pulmonary fibrosis and interstitial lung disease. Her own research uses qualitative
More news about: The Pulmonary Fibrosis Foundation
Apr 22, 2026, 08:45 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 22, 2026, 07:00 ET Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
monotherapy demonstrates greater anti-tumor activity than Dato-DXd (TROP-2 ADC approved in EGFR-mutant lung cancer) and izalontamab brengitecan (HER3-EGFR bispecific ADC in development for EGFR-mutant lung cancer). ATNM-400 also demonstrates greater anti-tumor activity than the EGFR-cMET bispecific antibody
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 07:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.
More news about: Genprex, Inc.
Apr 22, 2026, 07:00 ET Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting
antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 00:01 ET New Report: Half of U.S. Kids Are Breathing Dangerous Air Pollution
here.About the American Lung AssociationThe American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic
More news about: American Lung Association
Apr 21, 2026, 20:53 ET Kelun-Biotech Announces Three Clinical Study Results Selected for Oral Presentations at 2026 ASCO Annual Meeting
non-small cell lung cancer (NSCLC): Results from the randomized, controlled phase III OptiTROP-Lung05 studyPresentation Type: OralAbstract Number: 8506Session Date and Time: May 29, 3:12 PM-3:24 PM CDT | Lung Cancer-Non-Small
More news about: Kelun-Biotech
Apr 21, 2026, 20:28 ET 2026 ASCO | 科倫博泰3項研究成果入選2026美國臨床腫瘤學會年會口頭彙報
2026 ASCO展示的臨床研究成果具體包括：標題：蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗對比帕博利珠單抗一線治療PD-L1陽性晚期非小細胞肺癌(NSCLC)：隨機、對照III期研究(OptiTROP-Lung05)結果展示形式：口頭報告摘要#：8506會議日期和時間：當地時間5月29日15:12-15:24
More news about: 科倫博泰
Apr 21, 2026, 20:00 ET Innovent to Present New Clinical Data of IBI363（PD-1/IL-2α-biased bispecific fusion protein） at the 2026 ASCO Annual Meeting
Title: IBI363 (TAK-928) plus chemotherapy as first line (1L) treatment for advanced non-small cell lung cancer (NSCLC).Abstract Number: 8586Session Type: PosterSession Title: Lung Cancer/Non-Small Cell MetastaticSession Date & Time: May 31, 2026 9:00 AM-12:00 PM
More news about: Innovent Biologics
Apr 21, 2026, 18:50 ET /U P D A T E -- Nuvation Bio Inc./
another poster session at AACR, new preclinical data showed that taletrectinib inhibited the migration of lung cancer cells, suggesting the ability of taletrectinib to reduce the invasive capacity of lung cancer cells based on its tropomyosin receptor kinase B (TRKB) inhibition profile. In mechanistic studies,
More news about: Nuvation Bio Inc.
Apr 21, 2026, 16:53 ET GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at 2026 ASCO Annual Meeting
cancer2*. The Galleri test increases the number of cancers detected seven-fold when added to recommended screening for breast, cervical, colorectal and lung cancers, and has the lowest false positive rate of any MCED test on the market1,2,3,4,**The Galleri test doubles the number of cancers detected
More news about: GRAIL, Inc.
Apr 21, 2026, 16:05 ET TransMedics to Report First Quarter 2026 Financial Results on May 5, 2026
Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026.
More news about: TransMedics Group, Inc.
Apr 21, 2026, 16:05 ET Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
evaluating Zepzelca® (lurbinectedin) plus atezolizumab (Tecentriq®) as first-line maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC), including quality-adjusted time without symptoms or toxicity, as well as a rapid oral presentation on outcomes across SCLC molecular
More news about: Jazz Pharmaceuticals plc
Apr 21, 2026, 12:45 ET Dizal to Report Key Progress in its NSCLC Portfolio with Two Oral Presentations and a Poster During ASCO 2026
company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung cancer (NSCLC) pipeline will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2 in Chicago.
More news about: Dizal Pharmaceutical
Apr 21, 2026, 11:09 ET Crunch Care Launches The Power Edit, Supporting Mothers Navigating Cancer as Diagnoses Rise in Adults Under 50
than 187 rounds of chemotherapy, multiple courses of radiation, two major surgeries, immunotherapy clinical trials, alternative oncology treatments, lung ablation, and continuous medical evaluation to stay ahead of the disease. Her experience represents one of the few cases of extended survival at this
More news about: Crunch Care
Apr 21, 2026, 10:32 ET Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
that pivotal data for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated patients with advanced ALK-positive non-small cell lung cancer (NSCLC) from the global ALKOVE-1 Phase 1/2 clinical trial, in addition to preliminary data for TKI-naïve patients, will be presented during an
More news about: Nuvalent, Inc.
Apr 21, 2026, 10:01 ET Extracorporeal Membrane Oxygenation Market to Reach $952.2 Million by 2035, Growing at 5% CAGR
Growth and Opportunities:The extracorporeal membrane oxygenation (ECMO) market is growing quickly because more people are having heart and lung failure, technology is getting better, and more people are using it in intensive care units. The market is growing because more people are getting conditions
More news about: Allied Market Research
Apr 21, 2026, 09:04 ET The Dr. Gundry Podcast Celebrates 400 Episodes, Marking a Major Milestone in Health & Wellness Media
cardiothoracic surgeons before leaving his practice to pursue restorative medicine. Today, he is the founder and medical director of The International Heart and Lung Institute and The Centers for Restorative Medicine in Palm Springs and Montecito, California, where he has spent the past 25 years helping people restore
More news about: The Dr. Gundry Podcast
Apr 21, 2026, 08:30 ET IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025
liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including in the breast, kidney, lung, and liver.ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its
More news about: IceCure Medical
Apr 21, 2026, 08:00 ET Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger
technology. The Company's proprietary product pipeline includes treatments for central nervous system ("CNS") disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease ("COPD") and allergic bronchopulmonary aspergillosis ("ABPA"). Pulmatrix's product candidates
More news about: Pulmatrix Inc.
Apr 21, 2026, 07:00 ET Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy
Gene Therapy (quaratusugene ozeplasmid), the Company's lead drug candidate that is in development for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
More news about: Genprex, Inc.
Apr 21, 2026, 03:57 ET Wearable Technology Market Expected to Reach $183.2 Billion by 2031, Growing at a CAGR of 12.75% -- Allied Market Research
PerspectiveStructural Inflection Point for Wearable Tech Market With the largest-aged population globally, they require continuous non-invasive monitoring of heart, lung and brain health by detecting early symptoms. At the same time, healthcare systems pressed financially are transitioning to preventive care models —
More news about: Allied Market Research
Apr 20, 2026, 12:11 ET Texas Biomed advancing new approach methodologies (NAMs)
and machine learning/AI. Organoids are 3D cellular structures that are simplified, miniature representations of individual tissues or organs, such as lung, liver, heart and brain. Organ-on-a-chip systems – also called microphysiological systems (MPS) – are devices that aim to mimic dynamics within tissues,
More news about: Texas Biomedical Research Institute